Rare disease giant Shire plunked down an undisclosed sum to get its hands on a preclinical autoimmune drug candidate being developed by AB Biosciences. Source: BioSpace

Since 2013, Dr. Perlmutter has served as executive vice president of Merck and president of Merck Research Laboratories. Source: BioSpace

Artelo Biosciences and the NEOMED Institute announced today that they have entered into an exclusive global option and license agreement for NEO1940. Source: BioSpace

With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be. Source: BioSpace

The SEC filed a suit against “one or more unknown traders” while it seeks to identify the perpetrators. Source: BioSpace

A look at three small biotechs that big drugmakers are drooling over. Source: BioSpace

The FDA's Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD. Source: BioSpace

AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate. Source: BioSpace

the FDA has determined that it cannot approve the NDA in its present form and provides specific reasons for this action along with recommendations needed for resubmission. Source: BioSpace

Apostle, headquartered in Sunnyvale, Calif., hopes to file an IPO or establish other strong business collaborative routes in five years. Source: BioSpace